A2 Biotherapeutics

Focus: A2 Biotherapeutics is an early-stage immunotherapy biotech focused on cell-based therapies for oncology and regenerative medicine, headquartered in Agoura Hills, California. The company operates at the pre-revenue or early clinical stage with a portfolio anchored in allogeneic CAR T cell therapies and mesenchymal stem cell programs.

Oncology

Profile data last refreshed 18h ago · AI intelligence enriched 2w ago

Open Jobs

About A2 Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow A2 Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Apheresis

Solid Tumor, Adult

N/A

Clinical Trials (1)

NCT04981119Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

N/A

Help build intelligence for A2 Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Significant early-stage pipeline with 8 active programs spanning solid tumors and regenerative medicine, offering exposure to cutting-edge CAR T cell therapy development
Multiple Phase 1/2 programs (4 solid tumor assets) create near-term clinical catalysts and opportunities to shape first-in-human data
Focused immunotherapy focus area provides deep domain specialization vs. diversified competitors

Watch Out For

Zero currently hiring roles and no disclosed employee count or funding signal suggests possible financial constraints or hiring freeze
No Phase 3 programs in pipeline means 3-5+ years to potential regulatory milestones; early-stage clinical attrition risk is high
Lack of published data, disclosed financials, or recent news creates visibility gap on company momentum and funding runway

Generated by Claude from A2 Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

No additional intervention administered in this long term follow-up study

Solid Tumor Cancer

N/A

Clinical Trials (1)

NCT06885424A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

N/A

BEL-X-HG

Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT03256331Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients

Phase 1

A2B395

Solid Tumor, Adult

Phase 1/2

Clinical Trials (1)

NCT06682793A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Phase 1/2

A2B694

Solid Tumor, Adult

Phase 1/2

Clinical Trials (1)

NCT06051695A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Phase 1/2

allogeneic CAR T cell therapy

Solid Tumor, Adult

Phase 1/2

A2B530

Solid Tumor, Adult

Phase 1/2

Clinical Trials (1)

NCT05736731A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Phase 1/2

bone marrow mesenchymal stem cells

Osteoarthritis, Knee

Phase 2

Clinical Trials (1)

NCT05027581Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA)

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 7 clinical trials

Top TAs: Oncology

Publications: 25 in PubMed

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

6 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Data-informed optimization of CAR T-cell therapy long-term follow-up.

Journal for immunotherapy of cancer

2026

PMID:41974583

BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials.

Showing 5 of 10 publications

A2 Biotherapeutics

About A2 Biotherapeutics

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · A2 Biotherapeutics(2)

Open Jobs (0)

Hiring Trend

Research Publications(10)